Taxonomy of Candida parapsilosis complex isolated from neonates and the role of Hsp90 inhibitors to enhanced the antifungal activity of micafungin

Lett Appl Microbiol. 2024 May 3;77(5):ovae044. doi: 10.1093/lambio/ovae044.

Abstract

Species from Candida parapsilosis complex are frequently found in neonatal candidemia. The antifungal agents to treat this infection are limited and the occurrence of low in vitro susceptibility to echinocandins such as micafungin has been observed. In this context, the chaperone Hsp90 could be a target to reduce resistance. Thus, the objective of this research was to identify isolates from the C. parapsilosis complex and verify the action of Hsp90 inhibitors associated with micafungin. The fungal identification was based on genetic sequencing and mass spectrometry. Minimal inhibitory concentrations were determined by broth microdilution method according to Clinical Laboratory and Standards Institute. The evaluation of the interaction between micafungin with Hsp90 inhibitors was realized using the checkerboard methodology. According to the polyphasic taxonomy, C. parapsilosis sensu stricto was the most frequently identified, followed by C. orthopsilosis and C. metapsilosis, and one isolate of Lodderomyces elongisporus was identified by genetic sequencing. The Hsp90 inhibitor geladanamycin associated with micafungin showed a synergic effect in 31.25% of the isolates, a better result was observed with radicicol, which shows synergic effect in 56.25% tested yeasts. The results obtained demonstrate that blocking Hsp90 could be effective to reduce antifungal resistance to echinocandins.

Keywords: Hsp90; antifungal resistance; echinocandins.

MeSH terms

  • Antifungal Agents* / pharmacology
  • Benzoquinones / pharmacology
  • Candida / classification
  • Candida / drug effects
  • Candida / genetics
  • Candida parapsilosis* / drug effects
  • Candida parapsilosis* / genetics
  • Candida parapsilosis* / isolation & purification
  • Candidemia / microbiology
  • Drug Resistance, Fungal
  • Drug Synergism
  • Echinocandins / pharmacology
  • HSP90 Heat-Shock Proteins* / antagonists & inhibitors
  • HSP90 Heat-Shock Proteins* / genetics
  • HSP90 Heat-Shock Proteins* / metabolism
  • Humans
  • Infant, Newborn
  • Lactams, Macrocyclic / pharmacology
  • Lipopeptides / pharmacology
  • Micafungin* / pharmacology
  • Microbial Sensitivity Tests*

Substances

  • Antifungal Agents
  • Micafungin
  • HSP90 Heat-Shock Proteins
  • Echinocandins
  • Benzoquinones
  • Lipopeptides
  • Lactams, Macrocyclic
  • geldanamycin